P

Inventor

MUSTER THOMAS

AT28 patents
⚠️ This page may combine multiple inventors who share the name “MUSTER THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MUSTER THOMAS

5 patents
US10125374B2Nov 13, 2018

Influenza virus vector for virotherapy

MUSTER THOMAS1 citations50
US8778357B2Jul 15, 2014

Method for generation of RNA virus

MUSTER THOMAS0 citations48
US8741301B2Jun 3, 2014

Method for generation of RNA virus

MUSTER THOMAS0 citations48
US8691238B2Apr 8, 2014

High growth reassortant influenza A virus

MUSTER THOMAS0 citations46
US9771564B2Sep 26, 2017

Influenza virus

MUSTER THOMAS0 citations45

SINAI SCHOOL MEDICINE

4 patents
US6669943B1Dec 30, 2003

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

SINAI SCHOOL MEDICINE61 citations96
US6468544B1Oct 22, 2002

Interferon inducing genetically engineered attenuated viruses

SINAI SCHOOL MEDICINE73 citations94
US7588768B2Sep 15, 2009

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

SINAI SCHOOL MEDICINE21 citations92
US6866853B2Mar 15, 2005

Interferon inducing genetically engineered attenuated viruses

SINAI SCHOOL MEDICINE31 citations90

KATINGER HERMANN

3 patents
US5866694AFeb 2, 1999

Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

KATINGER HERMANN52 citations94
US5756674AMay 26, 1998

Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

KATINGER HERMANN31 citations90
US5693752ADec 2, 1997

Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

KATINGER HERMANN22 citations90

PALESE PETER

2 patents
US8057803B2Nov 15, 2011

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

PALESE PETER12 citations92
US8765139B2Jul 1, 2014

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

PALESE PETER2 citations62

AVIR GREEN HILLS BIOTECHNOLOGY

2 patents
US7510862B2Mar 31, 2009

Polynucleotide fragments of an infectious human endogenous retrovirus

AVIR GREEN HILLS BIOTECHNOLOGY4 citations55
US7282599B2Oct 16, 2007

Dithiocarbamate antiviral agents and methods of using same

AVIR GREEN HILLS BIOTECHNOLOGY0 citations39

POLYNUM SCIENT IMMUNBIOLOGISCH

1 patent
US5911989AJun 15, 1999

HIV-vaccines

POLYNUM SCIENT IMMUNBIOLOGISCH62 citations90

(unassigned)

1 patent
US6022726AFeb 8, 2000

Genetically engineered attenuated viruses

21 citations88

BRUNNHOFER ERWIN

1 patent
US8286396B2Oct 16, 2012

Plastic profile for window, door and facade elements

BRUNNHOFER ERWIN15 citations81

POLYMUN SCIENT IMMUNBIO FORSCH

1 patent
US6268484B1Jul 31, 2001

HIV-vaccines

POLYMUN SCIENT IMMUNBIO FORSCH16 citations80

ICAHN SCHOOL MED MOUNT SINAI

1 patent
US9387240B2Jul 12, 2016

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

ICAHN SCHOOL MED MOUNT SINAI1 citations63

BAXTER HEALTHCARE SA

1 patent
US9187732B2Nov 17, 2015

Replication deficient influenza virus for the expression of heterologous sequences

BAXTER HEALTHCARE SA3 citations59

VIVALDI BIOSCIENCES INC

1 patent
US12447204B2Oct 21, 2025

Prime-boost influenza vaccine

VIVALDI BIOSCIENCES INC0 citations56

Bia Separations Doo

1 patent
US10570376B2Feb 25, 2020

Method for influenza virus purification

Bia Separations Doo1 citations50

BLUESKY IMMUNOTHERAPIES GMBH

1 patent
US12350325B2Jul 8, 2025

Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2

BLUESKY IMMUNOTHERAPIES GMBH0 citations48

BLUE SKY VACCINES GMBH

1 patent
US10480013B2Nov 19, 2019

Influenza virus vector for virotherapy

BLUE SKY VACCINES GMBH0 citations45

AVIR GREEN HILLS BIOTECHNOLOGY RES DEV TRADE AG

1 patent
US8008460B2Aug 30, 2011

Polynucleotide fragments of an infectious human endogenous retrovirus

AVIR GREEN HILLS BIOTECHNOLOGY RES DEV TRADE AG0 citations42

HUMER JOHANNES

1 patent
US8541553B2Sep 24, 2013

Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein

HUMER JOHANNES0 citations38